CA2443092A1 - Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders - Google Patents

Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders Download PDF

Info

Publication number
CA2443092A1
CA2443092A1 CA002443092A CA2443092A CA2443092A1 CA 2443092 A1 CA2443092 A1 CA 2443092A1 CA 002443092 A CA002443092 A CA 002443092A CA 2443092 A CA2443092 A CA 2443092A CA 2443092 A1 CA2443092 A1 CA 2443092A1
Authority
CA
Canada
Prior art keywords
compound
lower alkyl
formula
free
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002443092A
Other languages
English (en)
French (fr)
Inventor
Michael Heinrich
Motowo Nakajima
Kenichi Koike
Atsushi Komiyama
Kouichi Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Oregon Health Science University
US Department of Veterans Affairs VA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2443092A1 publication Critical patent/CA2443092A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
CA002443092A 2001-04-05 2002-04-05 Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders Abandoned CA2443092A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0108606.5A GB0108606D0 (en) 2001-04-05 2001-04-05 Organic compounds
GB0108606.5 2001-04-05
PCT/US2002/010742 WO2002080925A1 (en) 2001-04-05 2002-04-05 Use of n-phenyl-2-pyrimidineamine derivativea against mast cell-based diseases like allergic disorders

Publications (1)

Publication Number Publication Date
CA2443092A1 true CA2443092A1 (en) 2002-10-17

Family

ID=9912339

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002443092A Abandoned CA2443092A1 (en) 2001-04-05 2002-04-05 Use of n-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders

Country Status (18)

Country Link
EP (1) EP1389113A1 (ru)
KR (2) KR20090034998A (ru)
CN (1) CN1529602A (ru)
AU (1) AU2002307140B2 (ru)
BR (1) BR0208663A (ru)
CA (1) CA2443092A1 (ru)
CZ (1) CZ20032705A3 (ru)
GB (1) GB0108606D0 (ru)
HU (1) HUP0303751A3 (ru)
IL (1) IL158061A0 (ru)
MX (1) MXPA03009058A (ru)
NO (1) NO325454B1 (ru)
NZ (1) NZ528934A (ru)
PL (1) PL363080A1 (ru)
RU (1) RU2304436C2 (ru)
SK (1) SK12312003A3 (ru)
WO (1) WO2002080925A1 (ru)
ZA (1) ZA200307563B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE343415T1 (de) 2001-06-29 2006-11-15 Ab Science Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen
JP2005500041A (ja) 2001-06-29 2005-01-06 アブ サイエンス 強力で選択的かつ非毒性のｃ−ｋｉｔ阻害剤
DK1401413T3 (da) 2001-06-29 2007-03-26 Ab Science Anvendelse af tyrosinkinaseinhibitorer til behandling af allergiske sygdomme
JP2004537537A (ja) 2001-06-29 2004-12-16 アブ サイエンス 炎症性疾患を治療するためのチロシンキナーゼ阻害剤の使用法
GB0201882D0 (en) * 2002-01-28 2002-03-13 Novartis Ag Organic compounds
AU2003226209B2 (en) * 2002-03-21 2008-10-23 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
US8450302B2 (en) 2002-08-02 2013-05-28 Ab Science 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors
CN100491374C (zh) 2002-08-02 2009-05-27 Ab科学公司 2-(3-氨基芳基)氨基-4-芳基-噻唑及其作为c-kit抑制剂的应用
WO2004076693A1 (en) * 2003-02-27 2004-09-10 Ab Science Tailored treatment suitable for different forms of mastocytosis
AU2003232650A1 (en) * 2003-05-06 2004-11-26 Il Yang Pharm Co., Ltd. N-phenyl-2-pyrimidine-amine derivatives and process for the preparation thereof
TWI324604B (en) 2003-06-18 2010-05-11 Novartis Ag New use of staurosporine derivatives
WO2005115385A1 (en) * 2004-05-24 2005-12-08 Ab Science Use of c-kit inhibitors for treating acne
CA2578122A1 (en) * 2004-08-27 2006-03-02 Gpc Biotech Ag Pyrimidine derivatives
JP5129123B2 (ja) * 2005-05-02 2013-01-23 ノバルティス アーゲー 全身性肥満細胞症の処置のためのピリミジルアミノベンズアミド誘導体の使用
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
CN102421430B (zh) * 2009-04-06 2014-06-25 纽若泰克制药株式会社 用于预防或治疗烧伤的药物组合物
CN103058935B (zh) * 2013-01-15 2015-05-06 四川大学 一种嘧啶类化合物及其制备方法和用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso

Also Published As

Publication number Publication date
GB0108606D0 (en) 2001-05-23
NO325454B1 (no) 2008-05-05
HUP0303751A3 (en) 2005-06-28
CN1529602A (zh) 2004-09-15
WO2002080925A1 (en) 2002-10-17
MXPA03009058A (es) 2004-11-22
HUP0303751A2 (hu) 2005-04-28
KR20090034998A (ko) 2009-04-08
BR0208663A (pt) 2004-03-09
IL158061A0 (en) 2004-03-28
PL363080A1 (en) 2004-11-15
NO20034414L (no) 2003-12-04
SK12312003A3 (sk) 2004-02-03
AU2002307140B2 (en) 2006-02-16
RU2003130635A (ru) 2005-02-10
NZ528934A (en) 2006-10-27
NO20034414D0 (no) 2003-10-02
ZA200307563B (en) 2004-04-21
RU2304436C2 (ru) 2007-08-20
EP1389113A1 (en) 2004-02-18
CZ20032705A3 (en) 2004-06-16
KR20040007485A (ko) 2004-01-24

Similar Documents

Publication Publication Date Title
AU2002307140B2 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
US8569305B2 (en) Treatment of tuberous sclerosis associated neoplasms
AU2002307140A1 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
CA2401812C (en) Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy
JP2017193553A (ja) 神経線維腫症の処置のためのピリミジルアミノベンズアミド誘導体
US8673930B2 (en) Pyrimidylaminobenzamide derivatives for systemic mastocytosis
US20120277246A1 (en) Use of N-Phenyl-2-pyrimidineamine Derivatives Against Mast Cell-based Diseases Like Allergic Disorders
US20050171182A1 (en) Methods and compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
BRPI0611092A2 (pt) derivados de pirimidilaminobenzamida para sìndrome hipereosinofìlica
AU2006200436A1 (en) Use of N-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
NZ547214A (en) Use of N-phenyl-2-pyrimidineamine derivatives against mast cell-based diseases like allergic disorders
JP2005508846A (ja) アレルギー性疾患のような肥満細胞系疾患に対するｎ−フェニル−２−ピリミジンアミン誘導体の使用
US20030191131A1 (en) Use of organic compounds

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued